These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38792861)

  • 21. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
    Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
    Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City.
    Chilimuri S; Sun H; Alemam A; Mantri N; Shehi E; Tejada J; Yugay A; Nayudu SK
    West J Emerg Med; 2020 Jul; 21(4):779-784. PubMed ID: 32726241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and outcome of Covid-19 illness and predictors of in-hospital mortality in Saudi Arabia.
    Abolfotouh MA; Musattat A; Alanazi M; Alghnam S; Bosaeed M
    BMC Infect Dis; 2022 Dec; 22(1):950. PubMed ID: 36526994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes].
    Yang H; Yang LC; Zhang RT; Ling YP; Ge QG
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Jun; 52(3):420-424. PubMed ID: 32541972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Associated with a Positive Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Suspected Cases Presenting with Pneumonia: A Retrospective Cohort Study in a Single Medical Center.
    Li Y; Shang Y; Yang Y; Wang M; Yu D; Su D; Liu L; Wang Q; Zhang X; Ren J; Chen H
    Respiration; 2020; 99(9):739-747. PubMed ID: 33207356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent lymphocyte reduction and interleukin-6 levels are independently associated with death in patients with COVID-19.
    Xu Y; Wang N; Shen X; Liu X; Liu H; Liu Y
    Clin Exp Med; 2023 Nov; 23(7):3719-3728. PubMed ID: 37310657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The informative value of CD3+CD4+ and CD3+CD8+ T-cell count and cHIS scale as predictors of severe COVID-19 when using interleukin-6 receptor blockers in the in-hospital setting.
    Kruglova TS; Fomina DS
    Ter Arkh; 2022 Dec; 94(11):1294-1302. PubMed ID: 37167168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation Between HbA1c Levels and Mortality Rates in Hospitalized COVID-19 Patients.
    Bhagat A; Buxton L; Hasan M
    Cureus; 2022 Nov; 14(11):e31347. PubMed ID: 36514608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.
    Khan M; Khan H; Khan S; Nawaz M
    J Med Microbiol; 2020 Aug; 69(8):1114-1123. PubMed ID: 32783802
    [No Abstract]   [Full Text] [Related]  

  • 34. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Use of ICD-9-CM Coding to Identify COVID-19 Diagnoses and Determine Risk Factors for 30-Day Death Rate in Hospitalized Patients in Italy: Retrospective Study.
    Giordani B; Burgio A; Grippo F; Barone A; Eugeni E; Baglio G
    JMIR Public Health Surveill; 2024 Feb; 10():e44062. PubMed ID: 38393763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of in-hospital mortality AND death RISK STRATIFICATION among COVID-19 PATIENTS aged ≥ 80 YEARs OLD.
    Covino M; De Matteis G; Polla DAD; Santoro M; Burzo ML; Torelli E; Simeoni B; Russo A; Sandroni C; Gasbarrini A; Franceschi F
    Arch Gerontol Geriatr; 2021; 95():104383. PubMed ID: 33676091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated CD8
    Bobcakova A; Barnova M; Vysehradsky R; Petriskova J; Kocan I; Diamant Z; Jesenak M
    Front Immunol; 2022; 13():861666. PubMed ID: 35392095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.
    Zhang S; Guo M; Duan L; Wu F; Hu G; Wang Z; Huang Q; Liao T; Xu J; Ma Y; Lv Z; Xiao W; Zhao Z; Tan X; Meng D; Zhang S; Zhou E; Yin Z; Geng W; Wang X; Zhang J; Chen J; Zhang Y; Jin Y
    Crit Care; 2020 Jul; 24(1):438. PubMed ID: 32678040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.